文章核心观点 Microchip Technology Incorporated宣布Steve Sanghi将永久担任公司首席执行官、总裁及董事会主席，董事会认为他能带领公司长期执行目标，他本人也期待继续服务公司实现目标 [1][2] 公司人事变动 - Steve Sanghi自2024年11月起临时担任公司首席执行官和总裁，现同意永久担任该职位，同时继续担任董事会主席 [1] - Steve Sanghi在2021年退休前曾担任Microchip首席执行官近30年 [1] 董事会看法 - 董事会很高兴Steve Sanghi同意永久担任首席执行官和总裁，自他临时履职以来采取果断行动制定并实施恢复计划，认为他是带领公司长期执行目标的最佳人选 [2] Steve Sanghi表态 - Steve Sanghi表示已领导Microchip超30年，期待长期继续服务公司，虽恢复计划部分已完成或基本实施，但实现长期运营模式等还需持续努力，感谢董事会信任 [2] 公司概况 - 公司是智能、互联和安全嵌入式控制解决方案的领先提供商，开发工具易用、产品组合全面，能帮助客户降低风险、成本和上市时间 [3] - 公司解决方案服务约109,000家客户，涵盖工业、汽车、消费、航空航天和国防、通信和计算市场 [3] - 公司总部位于亚利桑那州钱德勒，提供出色技术支持、可靠交付和质量 [3]

RAPID CITY, S.D., July 02, 2025 (GLOBE NEWSWIRE) -- Black Hills Corp. (NYSE: BKH) will announce its 2025 second-quarter earnings after the market closes Wednesday, July 30, 2025, and will host a live conference call and webcast at 11 a.m. EDT on Thursday, July 31, 2025, to discuss the company’s financial results. To participate by phone and ask a question during the live broadcast, participants can access the event directly at Black Hills Corp. Conference Call. Please allow at least five minutes to register ...

FLORHAM PARK, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the “Company”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the closing of its previously announced underwritten public offering for gross proceeds of approximately $6.9 million prior to deducting underwriting commissions and offering expenses. The offering includes participation from healthcare dedicated funds an ...

Proceeds to drive development of ONP-002, the Company’s lead intranasal drug candidate for mild traumatic brain injurySARASOTA, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering intranasal therapeutics for neurological disorders, today announced the successful closing of its previously announced public offering of Series H Convertible Preferred Stock and Warrants. The Company secured total gross proceeds of approximately $16.5 mi ...

FONAR Board of Directors Appoints Independent DirectorJuly 02, 2025 4:10 PM EDT | Source: Fonar CorporationMelville, New York--(Newsfile Corp. - July 2, 2025) - FONAR Corporation (NASDAQ: FONR), The Inventor of MR Scanning, today announced that on July 2, 2025, its board of directors appointed Mr. Robert M. Carrino as an independent director of the Company's board of directors. This appointment fills a vacancy on the board left by Ms. Claudette J.V. Chan, who recently retired from her position ...

WESTPORT, Conn., July 02, 2025 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle market businesses, announced today that its Board of Directors (the “Board”) has declared a quarterly cash distribution for each of its three preferred share series. This announcement underscores that in the wake of its ongoing investigation of Lugano, the Company’s diversified business model supports its continued ability to generate strong cash flow. The Board declared ...

ATHENS, Greece, July 02, 2025 (GLOBE NEWSWIRE) -- Euroseas Ltd. (NASDAQ: ESEA), an owner and operator of container carrier vessels and provider of seaborne transportation for containerized cargoes, announced today that its Board of Directors has called an annual meeting of the shareholders to be held on July 23, 2025, at 11:00 a.m. at the offices of Seward & Kissel LLP, located at 901 K Street NW, Suite 800, Washington, DC 20001. Shareholders of record at the close of business on June 25, 2025, are entitled ...

Acclarent AERA® Eustachian Tube Balloon Dilation System First Patient Enrolled in Acclarent AERA® Pediatric Registry PRINCETON, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company, is proud to announce enrollment of the first patient in the Acclarent AERA Pediatric Registry, a prospective, multi-center observational registry evaluating the real-world use of the AERA Eustachian Tube Balloon Dilation System in childre ...

公司诉讼事件 - Sarepta Therapeutics公司面临集体诉讼 指控其在2023年6月22日至2025年6月24日期间发布重大虚假或误导性声明 [3] - 诉讼涉及基因疗法ELEVIDYS的安全性问题 包括未披露患者重大安全风险及试验方案缺陷 [3] - 公司被指隐瞒ELEVIDYS严重不良反应 导致试验招募暂停并引发监管审查风险 [3] 法律程序进展 - 股东参与集体诉讼的截止日期为2025年8月25日 需通过指定链接登记 [4] - 登记股东将获得案件生命周期内的状态更新 无需承担参与成本 [4] - 牵头原告申请截止日期同为2025年8月25日 但非强制参与条件 [1][4] 涉事产品影响 - ELEVIDYS作为治疗杜氏肌营养不良的基因疗法 其现有及扩展批准风险因安全性问题加剧 [3] - 不良反应严重程度直接影响公司临床试验进程 包括暂停给药等操作 [3]

公司诉讼事件 - Fortrea Holdings Inc (NASDAQ: FTRE) 面临集体诉讼 涉及2023年7月3日至2025年2月28日期间购买股票的股东 [3] - 诉讼指控公司在上述期间发布 materially false and/or misleading statements [3] - 公司被指控高估长期项目(Pre-Spin Projects)对2025年收益的贡献 [3] - 公司被指控夸大退出过渡服务协议可能实现的成本节约 [3] - 公司2025年EBITDA目标被指夸大 [3] - 公司分拆后商业模式及业务/财务前景的可行性被指高估 [3] 诉讼时间节点 - 股东需在2025年8月1日前登记参与集体诉讼 [4] - 股东登记后将获得案件进展监控服务 [4] - 申请成为首席原告的截止日期为2025年8月1日 [4] 律师事务所信息 - The Gross Law Firm 负责此集体诉讼案件 [5] - 该律所专注于保护因欺骗、欺诈和非法商业行为受损的投资者权益 [5] - 律所致力于确保企业遵守负责任的商业实践和良好企业公民行为 [5]